ArticleNeuro-oncology2021

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma.

Martin van den Bent et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.